European regulators on Tuesday authorized the use of Biogen and Eisai’s Alzheimer’s treatment Leqembi for some early-stage ...

The Johnson & Johnson CEO subtly but assertively criticized the Trump administration’s plans for pharmaceutical tariffs, ...

A bipartisan group of 39 state attorneys general is calling on congressional leadership to pass a bill that would prohibit ...

A US trade probe into pharmaceuticals is underway. And it’s hitting many of the key aspects of the supply chain.

Boehringer Ingelheim licenses Cue Biopharma's CUE-501 bispecific antibody for $12M upfront, $345M in milestones to target autoimmune diseases via B cell depletion.

Boston and Dublin biotech Mural Oncology is laying off nearly all of its employees and ending clinical development of its IL-2 drug nemvaleukin alfa.

Sanofi's amlitelimab fails Phase 2 asthma trial at highest dose, but company sees path forward based on medium dose results in specific patient subgroup ...

The FDA has per­mit­ted eGe­n­e­sis to be­gin a clin­i­cal tri­al of a dial­y­sis-like sys­tem that in­volves us­ing a gene-edit­ed pig liv­er out­side of the body … ...

Attovia Therapeutics is turning fundraising announcements into an annual tradition. In June 2023, the San Carlos, CA-based startup launched with $60 million. Then in May 2024 ...

Johnson & Johnson is maintaining its 2025 financial guidance and raising its sales forecast despite President Donald Trump’s efforts to tariff pharmaceuticals.

Roche dev­as­tat­ed the An­gel­man syn­drome com­mu­ni­ty in 2023, when it end­ed clin­i­cal de­vel­op­ment of ru­gonersen, a treat­ment can­di­date … ...

Merck licenses Cyprumed's oral drug delivery platform in $493M deal to develop oral peptide formulations, potentially for GLP-1 drugs.